Marina Konopleva is the Director of Leukemia at Montefiore Cancer Center, while Emma Groarke is an Associate Research Physician at the NIH. They delve into the landscape of rare myeloid diseases like BPDCN, CMML, and VEXAS, discussing innovative therapies including Tagrexofaspa and IDH inhibitors. The conversation highlights the complexities in treatment due to patient variability and the significance of risk stratification in decision-making. They also emphasize the importance of collaborative research to enhance outcomes in these challenging conditions.